FAAH Enzyme

Plain-language summary

FAAH (fatty acid amide hydrolase) is an enzyme embedded in the membranes of cells throughout your body, especially in the brain and liver. Its main job is to chop up anandamide — a fatty molecule your body makes that acts on the same CB1 receptors as THC Strong evidence ^[1]. When FAAH works normally, anandamide signals briefly and then gets broken down. When FAAH is blocked or genetically less active, anandamide hangs around longer, and CB1 signaling is amplified — without the person ever taking cannabis ^[2].

This made FAAH one of the most attractive drug targets of the 2000s and 2010s. The pitch: inhibit FAAH, get cannabis-like benefits (pain relief, reduced anxiety) without the high, because you're only boosting endocannabinoids that are already there. Two decades later, that pitch has mostly not panned out clinically. No FAAH inhibitor is approved for any indication anywhere in the world.

This article is not medical advice. It summarizes what the published evidence does and does not show. Talk to a clinician before making treatment decisions.

What FAAH actually does

FAAH is a serine hydrolase — it uses a serine residue to cleave amide bonds. Its preferred substrate is anandamide (N-arachidonoylethanolamine, AEA) Strong evidence ^[1][3]. It also breaks down related lipids: oleoylethanolamide (involved in appetite and satiety), palmitoylethanolamide (PEA, involved in inflammation), and other N-acylethanolamines ^[3].

When you knock out the FAAH gene in mice, anandamide levels rise 10-15 fold in the brain, and the animals show reduced pain responses and reduced anxiety-like behavior in some assays Strong evidence ^[2]. In humans, a common genetic variant — C385A (rs324420) — produces a less stable FAAH enzyme, leading to modestly higher anandamide levels in carriers ^[4]. This variant has been linked observationally to lower anxiety and altered fear extinction, though effect sizes are small and replication is mixed Weak / limited ^[4][5].

The famous case of Jo Cameron, a Scottish woman who feels almost no pain or anxiety, involves a mutation in FAAH-OUT, a pseudogene that regulates FAAH expression. She has very low FAAH activity and elevated anandamide [evidence:strong — for the case, weak — for generalizability] ^[6]. She is, as far as we know, one person.

What probably works

Honestly: very little, in humans, with FAAH inhibitors as drugs.

What is solid is the basic pharmacology: FAAH inhibitors do raise anandamide levels in humans, confirmed by plasma measurements in Phase 1 trials Strong evidence ^[7]. The mechanism is real. The translation to clinical benefit is where things fall apart.

In animals, FAAH inhibition reliably reduces pain in inflammatory and neuropathic models and reduces anxiety-like behavior [evidence:strong, animal] ^[2][3]. That preclinical signal is part of why so many companies invested in this target.

What might work

Anxiety disorders. A Phase 2 trial of the FAAH inhibitor JNJ-42165279 in social anxiety disorder showed a modest reduction in symptoms versus placebo Weak / limited ^[8]. One trial, modest effect, not yet replicated or approved.

Cannabis use disorder. A Phase 2a trial of PF-04457845 in men with cannabis dependence reduced withdrawal symptoms and cannabis use during a 4-week treatment period Weak / limited ^[9]. Promising, but small, single-site, and not advanced to approval.

PTSD and fear extinction. Carriers of the FAAH C385A variant show enhanced fear extinction in laboratory paradigms, and a small study found PF-04457845 enhanced fear extinction recall in healthy volunteers Weak / limited ^[5][10]. No approved indication.

Pain. This is where FAAH inhibitors have most consistently failed. Pfizer's PF-04457845 did not beat placebo for osteoarthritis pain in a Phase 2 trial [evidence:strong, negative] ^[11]. Multiple other compounds have been dropped quietly.

What doesn't work / weak evidence

• FAAH inhibitors for chronic pain in humans. Repeatedly negative or null trials despite strong animal data [evidence:strong, negative] ^[11].
• 'Boost your endocannabinoids naturally' supplements (chocolate, exercise, kava, etc. marketed as FAAH inhibitors). Some compounds inhibit FAAH in vitro at concentrations far above what diet or supplements achieve in vivo [evidence:none to weak]. There is no good evidence any commercially marketed FAAH supplement meaningfully changes anandamide levels in people.
• Cannabis itself as a FAAH inhibitor. THC binds CB1 directly; it is not a meaningful FAAH inhibitor. CBD has weak FAAH inhibitory activity in some assays but the human relevance is unclear Disputed ^[12].
• The C385A variant as a predictor of cannabis response. Marketed by some consumer genetics services. Effect sizes are small and clinically unhelpful Weak / limited.

What we don't know

• Why FAAH inhibition works so well in rodents and so poorly in humans for pain. Hypotheses include species differences in endocannabinoid tone, compensatory upregulation of other degrading enzymes (MAGL, NAAA), and the wrong pain populations being tested.
• Whether dual FAAH/MAGL inhibitors or peripherally-restricted FAAH inhibitors will perform better. Some are in early development.
• The long-term safety of chronically elevated anandamide in humans. We have decades of data on chronic THC exposure but very little on chronic endogenous CB1 over-activation.
• Whether the Jo Cameron / FAAH-OUT phenotype can be safely mimicked pharmacologically. Probably not soon.

Comparison with standard treatments

For chronic pain, standard care (NSAIDs, duloxetine, gabapentinoids, opioids in some cases, physical therapy) has known, if imperfect, evidence. FAAH inhibitors have failed to beat placebo in head-to-head and placebo-controlled trials ^[11]. They are not an option.

For anxiety, SSRIs and SNRIs have decades of evidence and are approved. FAAH inhibitors have one modestly positive Phase 2 trial ^[8]. The comparison isn't close.

For cannabis use disorder, there are no FDA-approved pharmacotherapies. FAAH inhibition is one of several investigational approaches (alongside gabapentin, N-acetylcysteine, and CBD), none of which are first-line ^[9]. Cognitive behavioral therapy remains the best-supported intervention.

Compared to cannabis itself, a FAAH inhibitor would in theory raise only endogenous anandamide rather than flooding CB1 with exogenous THC. In practice, since no FAAH inhibitor is approved, this is a theoretical comparison.

Risks and the BIA 10-2474 disaster

In January 2016, a Phase 1 trial in Rennes, France, of the FAAH inhibitor BIA 10-2474 (Bial) caused the death of one healthy volunteer and severe neurological injury in four others Strong evidence ^[13][14]. Investigation concluded the toxicity was likely due to off-target effects of that specific compound — it inhibited several lipases beyond FAAH at high doses — rather than FAAH inhibition itself ^[14]. More selective FAAH inhibitors like PF-04457845 have not shown similar toxicity.

Still, the episode is a permanent reminder that 'targets the endocannabinoid system' is not synonymous with 'safe.'

Known or theoretical risks of FAAH inhibition include:

• Drowsiness, headache, dizziness (reported across trials)
• Theoretical: weight gain, metabolic effects (FAAH also processes oleoylethanolamide, a satiety signal)
• Theoretical: cognitive effects from sustained CB1 activation
• Unknown long-term effects

Again: this is not medical advice. If you are considering any cannabinoid-related therapy, talk to a clinician familiar with the endocannabinoid system.

Sources

How this page was made

Related

• Cannabis Use Disorder — A real DSM-5 diagnosis affecting roughly 1 in 5 regular users, with modest but growing evi...